

August 9, 2016

To
B S E Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai - 400 001

Scrip Code: 524558

To
The National Stock Exchange of
India Ltd
Exchange Plaza,
Bandra Kurla Complex
Bandra (E)
Mumbai - 400 001

**Scrip Code: NEULANLAB
Series: EQ**

Dear Sirs,

**Results Release and Revised Earnings Call Notice
Ref: Letter dated August 8, 2016**

We refer to the Earnings Call details sent to you vide our letter dated August 8, 2016, under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015

We would like to inform you that there has been a change in the schedule of the Earnings Call. Please find enclosed a copy of Revised Earnings Call details of Q1 FY 2017, for your information and records.

Thanking you,

Yours faithfully,
For Neuland Laboratories Limited



**Sarada Bhamidipati
Company Secretary**



Earning Conference Call:

Neuland Laboratories Limited will announce its results for the first quarter ended June 30th 2016 on Friday, August 12th, 2016. The results will also be made available on the website of the Company, www.neulandlabs.com.

Following the announcement, the management of the Company will host an Earnings Call on **Tuesday, August 16th 2016 at 1100 hrs.** The details of the earnings call are:

Date: August 16, 2016 Time: 1100 Hrs

Dial-in Number: +91 22 3960 0644

Secondary Number: +91 22 6746 4144

You can also [click here for the diamond pass and calendar invite to your inbox](#)

Other Numbers:

Local Access Number

6000 1221 (Available in - Ahmedabad, Bangalore, Bhubaneswar, Chandigarh, Chennai, Coimbatore, Delhi, Goa, Guntur, Gurgaon, Hyderabad, Indore, Jamshedpur, Kanpur, Kochi/Cochin, Kolhapur, Kolkata, Nagpur, Noida, Patna, Pune, Raipur, Rajkot, Surat, Trivandrum, Vadodara, Vijayawada)

3940 3977 (Available in - Ahmedabad, Bangalore, Chandigarh, Chennai, Gurgaon (NCR), Hyderabad, Kochi/Cochin, Kolkata, Lucknow, Pune)

International Toll Free Number

USA - 18667462133 | UK - 08081011573 | Singapore - 8001012045 | Hong Kong - 800964448

About Neuland Laboratories Limited (BSE:524558, NSE: NEULANLAB)

For over 32 years, Neuland Labs has been at the forefront of manufacturing APIs through its cGMP manufacturing facilities, working with customers in close to 80 countries. Neuland Labs has developed more than 300 processes and 75 APIs, and it has filed around 48 U.S. drug master files (DMFs) and a total of around 400 DMFs in the European Union (EU) and other countries. Its manufacturing facilities are inspected and approved by the U.S. FDA and other leading regulatory agencies. Its record of quality manufacturing and reliability is highlighted by cGMP certifications that include the U.S. FDA, TGA (Australia), EDQM (EU), German Health Authority, Anvisa (Brazil), EMA (EU), Cofepris (Mexico), KFDA (Korea), PMDA (Japan), ISO 9001, ISO14001, OHSAS18001 and ISO 27001. For more information, visit www.NeulandLabs.com.

For Queries:

Neuland: ir@neulandlabs.com or Ankit Gupta: ankitgupta@christensenir.com